ANN ARBOR – Rubicon Genomics has partnered with Diagenode SA to integrate Rubicon’s ThruPLEX technology into Diagenode’s epigenetics platforms to increase the efficiency and quality of DNA sample preparation for chromatin immunoprecipitation applications.
The new agreement allows Diagenode to incorporate the Rubicon ThruPLEX-FD technology into its new MicroPLEX Library Preparation Kit for ChIP-seq studies requiring very small amounts of sample.
Rubicon is a leading provider of sample-specific pre-analytical processes to improve the performance and capabilities of DNA analytical platforms. Its ThruPLEX-FD NGS Prep kits for synthesis and amplification of ChIP DNA for next generation sequencing use a one-tube, three-step process that is efficient, fast, and produces high quality DNA from small samples.
Diagenode?s products increase the efficiency and speed of the process used to precipitate and recover DNA for ChIP applications from very small amounts of chromatin. The combination of these two patented technologies will decrease the time and labor needed for ChIP-sequencing by almost 10 hours and provide researchers with high quality ChIP-seq and ChIP-chip results from small samples, reducing the number of cells needed to conduct ChIP analyses by a minimum of 100-fold.
?This partnership with Diagenode extends the reach of our proprietary technology. Diagenode is a leader in the ChIP market and our ThruPLEX technology is ideal for use in ChIP studies. This partnership is an important example of our collaboration strategy that focuses on combining complementary technologies to offer complete solutions to the research community,? noted James Koziarz, CEO of Rubicon Genomics. Rubicon intends to complete additional non-exclusive distribution agreements with leaders in other segments of the growing market for DNA and RNA analysis.
Diagenode has developed and validated reagents and equipment that reduce the number of cells needed to conduct analyses by 10 to 100-fold. This allows researchers to grow or harvest fewer cells, decreasing time and expense, and also enables studies of small subpopulations of cells. Combining these properties with the advantages of ThruPLEX-FD increases the quality of the sequencing results and is expected to enhance the value of ChIP as a tool for epigenomic research.
